Compare Amazon.com Inc (AMZN) vs AstraZeneca plc (AZN) Price & Performance

Amazon (AMZN) trades at $244.19, down 0.47% on the day but maintains strong bullish technical momentum with support at $241. The company demonstrates robust fundamentals with 2025 revenue of $716.92B and net income of $77.67B, representing 10.83% profit margin. Recent Q1 2026 earnings beat expectations with EPS of $2.78 versus $1.63 expected, while analyst consensus remains overwhelmingly positive with 88.3% buy ratings.

Amazon's outlook remains favorable with continued revenue growth and expanding profitability, though significant capital expenditures for AI infrastructure and competitive pressures in e-commerce present risks. The stock trades at a P/E of 29.35, offering growth potential relative to the consensus price target of $320.75, representing 31% upside from current levels.

AstraZeneca (AZN) trades at $171.61, down 3.85% following a Phase 3 clinical trial failure for its Wainua heart drug. The stock faces bearish technical signals with support at $167 and resistance at $177. Fundamentally, the company maintains strong profitability with 17.19% net margins and robust revenue growth, reaching $58.74B in 2025. Analyst consensus remains positive with 47.5% buy ratings despite recent setbacks.

The outlook remains cautiously optimistic as AstraZeneca's core business fundamentals remain intact with improving cash flow and debt reduction. However, pipeline execution risks and clinical trial uncertainties present near-term headwinds. Long-term investors may find value at current levels given the company's strong market position and financial health.